SSY Group Ltd. has announced a significant development in its product portfolio with the approval for drug production and registration of two products by the National Medical Products Administration of China (NMPA). The group received approval for its Calcium Gluconate and Sodium Chloride Injection (100ml), primarily used for treating acute hypocalcemia, magnesium poisoning, and fluoride poisoning. Additionally, the NMPA approved SSY Group's Potassium Chloride Granules, intended for the treatment and prevention of hypokalemia. This announcement is part of SSY Group's effort to keep shareholders and potential investors informed about its latest business developments.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief on June 04, 2025, and is solely responsible for the information contained therein.